# 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

> **NCT06896188** · PHASE1 · RECRUITING · sponsor: **Anwaar Saeed** · enrollment: 12 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Retifanlimab
- **DRUG:** Chemotherapy
- **DRUG:** 9-ING-41

## Key facts

- **NCT ID:** NCT06896188
- **Lead sponsor:** Anwaar Saeed
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06896188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06896188, "9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06896188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*